Dr. Reddy’s Laboratories Ltd announced that it has launched Nystatin and Triamcinolone Acetonide Cream, USP, in the United States market, approved by the U.S. Food & Drug Administration (USFDA).
Nystatin and Triamcinolone Acetonide Cream, USP is the generic equivanent of Nystatin and Triamcinolone Acetonide Cream, USP 100,000 units/g- 0.1% manufactured by Taro Pharmacueticals USA Inc.
The generic had U.S. sales of approximately $119 million MAT for the most recent twelve months ended in October 2016 according to IMS Health*.Dr. Reddy’s Nystatin and Triamcinolone Acetonide Cream, USP is available in tube sizes of 15g, 30g and 60g.
About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com